Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.

Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS.

Am J Surg Pathol. 2012 Dec;36(12):1761-70. doi: 10.1097/PAS.0b013e318263207c.

PMID:
23026928
2.
3.

Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.

McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, Mun LJ, Ellison TA, Wolfgang CL, Choti MA, Schulick RD, Edil BH, Hruban RH.

Am J Surg Pathol. 2013 Nov;37(11):1671-7. doi: 10.1097/PAS.0000000000000089.

4.

Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.

Voss SM, Riley MP, Lokhandwala PM, Wang M, Yang Z.

Am J Surg Pathol. 2015 Jan;39(1):13-24. doi: 10.1097/PAS.0000000000000341.

PMID:
25353284
5.

Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count.

Adsay V.

Am J Surg Pathol. 2012 Dec;36(12):1743-6. doi: 10.1097/PAS.0b013e318272ff77. No abstract available.

PMID:
23154766
6.

Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.

Remes SM, Tuominen VJ, Helin H, Isola J, Arola J.

Am J Surg Pathol. 2012 Sep;36(9):1359-63. doi: 10.1097/PAS.0b013e3182632038.

PMID:
22895268
7.

The importance of clinical information in patients with gastroenteropancreatic neuroendocrine tumor.

Kudo A, Akashi T, Kumagai J, Ban D, Inokuchi M, Kojima K, Kawano T, Tanaka S, Arii S.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2450-3.

PMID:
22584507
8.

Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors.

Matsukuma K, Olson KA, Gui D, Gandour-Edwards R, Li Y, Beckett L.

Mod Pathol. 2017 Apr;30(4):620-629. doi: 10.1038/modpathol.2016.225. Epub 2017 Jan 13.

9.

Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.

Ozkara S, Aker F, Yesil A, Senates E, Canbey C, Yitik A, Gonen C.

Hepatogastroenterology. 2013 Oct;60(127):1665-72.

PMID:
24627925
10.

Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.

Singh S, Hallet J, Rowsell C, Law CH.

Eur J Surg Oncol. 2014 Nov;40(11):1517-22. doi: 10.1016/j.ejso.2014.06.016. Epub 2014 Jul 24.

PMID:
25088936
11.

The potential value of phosphohistone-h3 mitotic index determined by digital image analysis in the assessment of pancreatic endocrine tumors in fine-needle aspiration cytology specimens.

Draganova-Tacheva R, Bibbo M, Birbe R, Daskalakis C, Solomides C.

Acta Cytol. 2013;57(3):291-5. doi: 10.1159/000350885. Epub 2013 Apr 25.

PMID:
23635399
12.

A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.

Zhong F, Bi R, Yu B, Yang F, Yang W, Shui R.

PLoS One. 2016 Feb 29;11(2):e0150505. doi: 10.1371/journal.pone.0150505. eCollection 2016.

13.

Accuracy of visual assessments of proliferation indices in gastroenteropancreatic neuroendocrine tumours.

Young HT, Carr NJ, Green B, Tilley C, Bhargava V, Pearce N.

J Clin Pathol. 2013 Aug;66(8):700-4. doi: 10.1136/jclinpath-2012-201217. Epub 2013 May 23.

PMID:
23703851
14.
15.

The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS.

Am J Surg Pathol. 2015 May;39(5):683-90. doi: 10.1097/PAS.0000000000000408.

16.

Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.

Pasaoglu E, Dursun N, Ozyalvacli G, Hacihasanoglu E, Behzatoglu K, Calay O.

Ann Diagn Pathol. 2015 Apr;19(2):81-7. doi: 10.1016/j.anndiagpath.2015.01.001. Epub 2015 Jan 9.

PMID:
25702616
17.
18.

A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue.

Laurinavicius A, Plancoulaine B, Laurinaviciene A, Herlin P, Meskauskas R, Baltrusaityte I, Besusparis J, Dasevicius D, Elie N, Iqbal Y, Bor C.

Breast Cancer Res. 2014;16(2):R35.

19.

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.

Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M.

Mod Pathol. 2010 Jun;23(6):824-33. doi: 10.1038/modpathol.2010.58. Epub 2010 Mar 19.

20.

Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors.

Goodell PP, Krasinskas AM, Davison JM, Hartman DJ.

Am J Clin Pathol. 2012 Apr;137(4):576-82. doi: 10.1309/AJCP92UCXPJMMSDU.

PMID:
22431534

Supplemental Content

Support Center